company background image
TCRT

Alaunos Therapeutics NasdaqGS:TCRT Stock Report

Last Price

US$0.87

Market Cap

US$187.7m

7D

-9.8%

1Y

-32.4%

Updated

28 Nov, 2022

Data

Company Financials +
TCRT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

TCRT Stock Overview

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies.

Alaunos Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alaunos Therapeutics
Historical stock prices
Current Share PriceUS$0.87
52 Week HighUS$4.01
52 Week LowUS$0.41
Beta0.18
1 Month Change-26.72%
3 Month Change-63.82%
1 Year Change-32.40%
3 Year Change-82.94%
5 Year Change-80.00%
Change since IPO-73.17%

Recent News & Updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Shareholder Returns

TCRTUS BiotechsUS Market
7D-9.8%0.4%1.3%
1Y-32.4%-14.4%-18.5%

Return vs Industry: TCRT underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: TCRT underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is TCRT's price volatile compared to industry and market?
TCRT volatility
TCRT Average Weekly Movement21.1%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: TCRT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: TCRT's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a41Kevin Boylehttps://www.alaunos.com

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute.

Alaunos Therapeutics, Inc. Fundamentals Summary

How do Alaunos Therapeutics's earnings and revenue compare to its market cap?
TCRT fundamental statistics
Market CapUS$187.69m
Earnings (TTM)-US$40.36m
Revenue (TTM)US$2.91m

64.5x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TCRT income statement (TTM)
RevenueUS$2.91m
Cost of RevenueUS$48.20m
Gross Profit-US$45.29m
Other Expenses-US$4.92m
Earnings-US$40.36m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin-1,555.82%
Net Profit Margin-1,386.64%
Debt/Equity Ratio70.6%

How did TCRT perform over the long term?

See historical performance and comparison